Adult survivors of childhood cancer often und

Via Peters

Embargoed until 4 a.m. CT/5 a.m. ET Wednesday, June 8, 2022 DALLAS, June 8, 2022 — Adults who survive childhood cancer have a higher risk of cardiovascular disease than the general population, yet they are 80% more likely to be undertreated for several cardiovascular risk factors: hypertension (also called high blood pressure), diabetes and high […]

Next phases of breast cancer drug research coming to RI

Via Peters

PROVIDENCE, R.I. (WPRI) — Advancements in a drug targeting breast cancer growth have oncologists hopeful about potential treatment options for patients with advanced forms of the disease. Results from the DESTINY-Breast04 Phase III trial showed the intravenous drug Enhertu, also known as trastuzumab deruxtecan, demonstrated “superior and clinically meaningful” progression-free and […]

Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer

Via Peters

This research complies with all relevant ethical regulations: The Sloane project, United Kingdom National Health Service Breast Screening Programme, was approved by the UK Health Research Authority (Ethical approval REF 08/S0703/147, 19/LO/0648); The Dutch DCIS cohort study, a Netherlands Cancer Registry (NCR; reference no 12.281), nationwide network and registry of […]

Time-Restricted Eating May Reduce CVD Risk After Breast Cancer

Via Peters

Time-restricted eating reduced cardiovascular risk among older breast cancer survivors, a single-group feasibility study suggests. The results show a 15% relative decline in cardiovascular risk, measured using the Framingham Risk Score, among at-risk breast cancer survivors (BCS) after only 8 weeks of following a time-restricted eating regimen, reported Amy A. Kirkham, PhD, […]

Antibody-Drug Conjugates May Represent the Future of HER2-Low Breast Cancer Treatment

Via Peters

Emerging data with novel antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan-nxki (Enhertu), vic-trastuzumab duocarmazine, and disitamab vedotin (Aidixi) are showing encouraging activity in HER2-low breast cancer. Paolo Tarantino, MD, said this data suggests that the classification of HER2 should go beyond merely positive or negative. “In the future, we will […]

Adjuvant Everolimus Fails to Stop Recurrence in Early High-Risk Breast Cancer

Via Peters

Adding mTOR inhibitor everolimus (Afinitor) to adjuvant endocrine therapy failed to improve disease-free survival (DFS) in high-risk hormone receptor-positive/HER2-negative (HR+/HER2-), a large randomized trial showed. Three-year DFS was 88% with everolimus plus endocrine therapy and 89% with placebo plus endocrine therapy. Tolerability figured prominently in the results, as more than […]